Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study
| dc.contributor.author | Fu, Tommy | |
| dc.contributor.author | Zhang, Lei | |
| dc.contributor.author | Cicero, Sherri | |
| dc.contributor.author | Witzig, Thomas E. | |
| dc.contributor.author | Besisik, Sevgi | |
| dc.contributor.author | Goy, Andre | |
| dc.contributor.author | Sinha, Rajni | |
| dc.contributor.author | Williams, Michael E. | |
| dc.contributor.author | Drach, Johannes | |
| dc.contributor.author | Ramchandren, Radhakrishnan | |
| dc.contributor.author | Robertson, Michael J. | |
| dc.contributor.author | Avivi, Irit | |
| dc.contributor.author | Rowe, Jacob M. | |
| dc.contributor.author | Herbrecht, Raoul | |
| dc.contributor.author | Van Hoof, Achiel | |
| dc.contributor.author | Egyed, Miklos | |
| dc.date.accessioned | 2021-03-05T08:14:36Z | |
| dc.date.available | 2021-03-05T08:14:36Z | |
| dc.identifier.citation | Goy A., Sinha R., Williams M. E. , Besisik S., Drach J., Ramchandren R., Robertson M. J. , Avivi I., Rowe J. M. , Herbrecht R., et al., "Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study", 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2012, cilt.120 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_97d632ed-faba-4331-8b26-256e0c046c59 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/102208 | |
| dc.language.iso | eng | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Hematoloji | |
| dc.subject | HEMATOLOJİ | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.title | Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 "EMERGE" Study | |
| dc.type | Bildiri | |
| dc.contributor.department | Hackensack University Medical Center , , | |
| dc.identifier.volume | 120 | |
| dc.contributor.firstauthorID | 140747 |
Bu öğenin dosyaları:
| Dosyalar | Boyut | Biçim | Göster |
|---|---|---|---|
|
Bu öğe ile ilişkili dosya yok. |
|||
Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.
-
Bildiri [64839]